Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5278 clinical trials
Featured trial
Parkinson's Progression Markers Initiative Online (PPMI Online)

Parkinson's Progression Markers Initiative Online (PPMI online) is part of the broader Parkinson’s Progression Markers Initiative aimed at better understanding who gets Parkinson’s disease and

Accepts healthy volunteers
Online studies
  • 162 views
  • 14 Sep, 2022
  • 1 location
  • Online study
Featured trial
The Orchestra Study: An 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

 whether an investigational medication known as UCB0599 can slow the progression of Parkinson’s disease and whether it is efficacious and well tolerated (which means whether it works

motor symptoms
bradykinesia
dopamine
hoehn and yahr scale
movement disorder
  • 350 views
  • 11 Nov, 2022
  • 116 locations
Featured trial
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS)

oligoclonal bands
disease or disorder
  • 110 views
  • 09 Nov, 2022
  • 11 locations
Featured trial
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

Our team of medical professionals is evaluating an investigational drug that is designed to slow the progression of Alzheimer’s disease. The study drug, ALZ-801, is a tablet that is taken twice

mild dementia
mini-mental state examination
apolipoprotein e
dementia
  • 76 views
  • 20 Sep, 2022
  • 79 locations
Featured trial
Randomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Small Cell Lung Cancer Patients With CEACAM5 Positive Tumors (CARMEN-LC03)  

Primary Objectives: Study is designed with two primary endpoints that will be analyzed on randomized participants at the time of the cutoff date for each given analysis (progression free

  • 134 views
  • 05 Dec, 2022
  • 5 locations
Featured trial
PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

This study consists of 2 parts. Part 1 of the study is conducted to evaluate the efficacy, safety, and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's Disease who are not receiving dopaminergic therapy. Part 2 is an optional long term extension study for …

early parkinson's
  • 51 views
  • 08 Dec, 2022
  • 75 locations
Featured trial
The Orchestra Study: An 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

Parkinson’s disease (newly diagnosed or early-stage disease) from several countries across North America and Europe. As it is assessing disease and symptom progression over a long period of time, the Orchestra

  • 0 views
  • 11 Nov, 2022
  • 41 locations
Featured trial
Study in Parkinson Disease of Exercise (SPARX3)

primary objective is to test whether the progression of the signs of Parkinson's disease is attenuated at 12 months in among persons who have not initiated medication for Parkinson Disease (PD) when they

SPECT Scan
datscan
movement disorder
  • 169 views
  • 07 Oct, 2022
  • 26 locations
Featured trial
Genotypic Influences on Network Progression in Parkinson's Disease

The goal of this research study is to help scientists better understand how mutations in the GBA (glucocerebrosidase beta acid) gene affects patients with Parkinson’s disease. Mutations in the GBA gene are the most common genetic risk factors for Parkinson's, affecting about 10 percent of the more than 6 million …

antiparkinsonian agents
  • 49 views
  • 01 Feb, 2022
  • 1 location
Featured trial
GAIN: GingipAIN Inhibitor for Treatment of Alzheimer's Disease

GAIN is a clinical trial evaluating whether an investigational drug is safe and can stop the progression of Alzheimer’s Disease by reducing bacterial damage in the brain. The P

senile plaques
  • 153 views
  • 08 Dec, 2020
  • 1 location